Silexion Therapeutics Ltd.
SLXNW · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $21 | $116 | $284 | $281 |
| - Cash | $1,187 | $4,595 | $8,259 | $39 |
| + Debt | $4,491 | $171 | $271 | $0 |
| Enterprise Value | $3,325 | -$4,308 | -$7,704 | $242 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$25 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$16,432 | -$4,636 | $584 | -$755 |
| % Margin | – | – | – | – |
| Net Income | -$16,443 | -$4,942 | $584 | -$755 |
| % Margin | – | – | – | – |
| EPS Diluted | 25.49 | 0.39 | 0.35 | -0.46 |
| % Growth | 6,435.9% | 11.4% | 176.1% | – |
| Operating Cash Flow | -$8,396 | -$4,529 | -$3,335 | -$1,407 |
| Capital Expenditures | -$22 | -$12 | -$40 | -$0 |
| Free Cash Flow | -$8,418 | -$4,541 | -$3,375 | -$1,407 |